Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation

World Journal of Urology

Volumn 15, Issue 3, 1997, Pages 155-164

  Ryall, R L ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM OXALATE;

ANIMAL; CHEMISTRY; CRYSTALLIZATION; HUMAN; MACROMOLECULE; MOLECULAR WEIGHT; RAT; REVIEW; URINE; UROLITHIASIS;

ANIMALS; CALCIUM OXALATE; CRYSTALLIZATION; HUMANS; MACROMOLECULAR SUBSTANCES; MOLECULAR WEIGHT; RATS; URINARY CALCULI; URINE;

EID: 0030633823     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02201852     Document Type: Article

References (141)

1. Addadi L, Weiner S (1985) Interactions between acidic proteins and crystals: stereochemical requirements in biomineralization. Proc Natl Acad Sci USA 82: 4110-4114
2. Akinci N, Esen T, Kocak T, Ozsoy C, Tellaloglu S (1992) The role of inhibitor deficiency in urolithiasis. I. Rationale of urinary magnesium, citrate, pyrophosphate and glycosaminoglycan determinations. Eur Urol 19: 240-243
3. Atmani F, Khan SR (1995) Characterization of uronic-acidrich inhibitor of calcium oxalate crystallization isolated from rat urine. Urol Res 23: 95-101
4. Atmani F, Lacour B. Drücke T, Daudon M (1993) Isolation and purification of a new glycoprotein from human urine inhibiting calcium oxalate crystallization. Urol Res 21:6
5. Atmani F, Lacour B, Strecker G. Parvy P, Drücke T, Daudon M (1993) Molecular characteristics of uronic-acid-rich protein, a strong inhibitor of calcium oxalate crystallization in vitro. Biochem Biophys Res Commun 191: 1158-1165
6. Atmani F, Lacour B, Jungers P. Drücke T, Daudon M (1994) Reduced inhibitory activity of uronic-acid-rich protein (UAP) in the urine of stone formers. Urol Res 22: 257-260
7. Atmani F, Mizon J, Khan SR (1996) Identification of uronicacid-rich protein as urinary bikunin, a light chain of inter-atrypsin inhibitor. Eur J Biochem 236: 984-990
8. Atmani F, Opalko FJ, Khan SR (1996) Association of urinary macromolecules with calcium oxalate crystals induced in vitro in normal human and rat urine. Urol Res 24: 45-50
9. Bach D, Hesse A, Strenge A, Vahlensieck W (1981) Magnesium excretion in urine on condition of individual standard diet in healthy controls and calcium oxalate stone formers. In: Smith LH, Robertson WG, Finlayson B (eds) Urolithiasis: clinical and basic research. Plenum, New York, pp 45-49
10. Baggio B, Gambaro G, Favaro S, Borsatti A, Pavanello L, Siviero B, Zaccjello G, Rizzoni GF (1983) Juvenile renal stone disease: a study of urinary promoting and inhibiting factors. J Urol 130: 1133-1135
11. Baggio B, Gambaro G, Cicerello E. Mastrosimone S. Marzaro G, Borsatti A, Pagano F (1987) Urinary excretion of glycosaminoglycans in urological disease. Clin Biochem 20: 449-450
12. Baumann JM, Bisaz S, Felix R, Fleisch H. Ganz U, Russell RGG (1977) The role of inhibitors and other factors in the pathogenesis of calcium-containing renal stones. Clin Sci Mol Med 53: 141-148
13. Bichler KH, Kirchner C, Ideler V (1976) Uromucoid excretion of normal individuals and stone formers. Br J Urol 47: 733-738
14. Boyce WH (1968) Organic matrix of human urinary concretions. Am J Med 45: 673-683
15. Boyce WH. Garvey FK (1956) The amount and nature of the organic matrix in urinary calculi: a review. J Urol 76: 213-227
16. Boyce WH, King J, Fielden M (1962) Total non-dialyzable solids (TNDS) in human urine XIII. Immunological detection of a component peculiar to renal calculons matrix and to urine of calculons patients. J Clin Invest 41: 1180-1189
17. Brown LF. Berse B, Van De Water L, Papadopoulos-Sergiou A. Perruzzi ÇA. Manseau EJ, Dvorak HF, Senger DR (1992) Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Biol Cell 3: 1169-1180
18. Canary JJ, Meloni CR, Cline D, Grossman E (1964) The renal clearance of citrate in man. Metabolism 13: 21-30
19. Cao LC, Boevé ER, Schröder FH, Robertson WG. Ketelaars GAM. De Bruijn (1992) The effect of two new semi-synthetic glycosaminoglycans (G871, G872) on the zeta potential of calcium oxalate crystals and on growth and agglomeration. J Urol 147: 1643-1646
20. Caudarella R. Stefani F, Rizzoli E. Malavolta N, D'Antuono G (1983) Preliminary results of glycosaminoglycans excretion in normal and stone forming subjects: relationship with uric acid excretion. J Urol 129: 665-667
21. Cramer W (1932) Experimental production of kidney lesion; by diet. Lancet II: 174-175
22. Crassweller PO, Oreopoulos DG, Toguri A Husdan H, Wilson DR. Rapoport A (1978) Studies in inhibitors of calcification and levels of urine saturation with calcium oxalate in recurrent stone patients. J Urol 120: 6-10
23. Crawford JE, Crematy EP, Alexander AE (1968) The effect ol natural and synthetic polyelectrolytes on the crystallization ol calcium oxalate. Aust J Chem 21: 1067-1072
24. Dawson CJ, Grover PK, Ryall RL (1996) Inter-a-trypsin inhibitor in urine, calcium oxalate crystals and calcium stones. In: Pak CYC, Resnick MI, Preminger GM (eds) Urolithiasis 1996. Millet, Dallas, pp 275-276
25. Dent CE, Sutor DJ (1971) Presence or absence of inhibitor ol calcium oxalate crystal growth in urine of normals or stone formers. Lancet II: 772-778
26. Doremus RH, Teich S, Silvis PX (1978) Crystallization of calcium oxalate from synthetic urine. Invest Urol 15: 469-472
27. Doyle IR, Ryall RL, Marshall VR (1991) Inclusion of proteins into calcium oxalate crystals precipitated from human urine: a highly selective phenomenon. Clin Chem 37: 1589-1594
28. Drach GW, Thorson S, Randolph AD (1980) Effects of urinary organic macromolecules on crystallisation of calcium oxalate: enhancement of nucleation. J Urol 123: 519-523
29. Elliot JS, Ribiero ME (1972) The urinary excretion of citrate, hippuric acid and lactic acid in normal adults and in patients with calcium oxalate urinary calculus disease. Invest Urol 10: 102-106
30. Fellström B, Danielson BG. Ljunghall S, Wikström B (1986) Crystal inhibition: the effects of polyanions on calcium oxalate crystal growth. Clin Chim Acta 158: 229-235
31. Fleisch H, Bisaz S (1962) Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol 203: 671-675
32. Fleisch H, Bisaz S (1962) Mechanism of calcification: inhibitory role of pyrophosphate. Nature 195: 911
33. Goldberg JM, Collier E (1972) Specific isolation and analysis of mucopolysaccharides (glycosaminoglycans) from human urine. Clin Chim Acta 41: 19-27
34. Grant AMS, Baker LRI, Neuberger A (1973) Urinary Tamm-Horsfall glycoprotein in certain kidney diseases and its content in renal and bladder calculi. Clin Sci 44: 377-384
35. Grases F, Gil JJ, Conte A (1989) Glycosaminoglycans inhibition of calcium oxalate crystalline growth and promotion of crystal aggregation. Coll Surf 36: 29-38
36. Hallson PC, Rose GA (1976) Crystalluria in normal subjects and stone formers with and without thiazide and cellulose phosphate treatment. Br J Urol 48: 515-524
37. Hallson PC, Rose GA (1979) Uromucoids and urinary stone formation. Lancet I: 1000-1002
38. Hallson PC, Rose GA, Sulaiman S (1982) Magnesium reduces calcium oxalate crystal formation in human whole urine. Clin Sci 62: 17-19
39. Hallson PC, Rose GA, Sulaiman S (1983) Pyrophosphate does not influence calcium oxalate or calcium phosphate crystal formation in concentrated whole human urine. Urol Res 11: 151-154
40. Hallson PC, Rose GA, Sulaiman S (1983) Raising urinary citrate lowers calcium oxalate and calcium phosphate crystal formation in whole urine. Urol Int 38: 179-181
41. Harangi F. Györke Z, Melegh B (1996) Urinary glycosaminoglycan excretion in healthy and stone forming children. Pediatr Nephrol 10: 555-558
42. Hastings AB, McLean FC, Eichelberger L, Hall JL, Da Costa E (1934) The ionization of calcium, magnesium and strontium citrates. J Biol Chem 107: 351-370
43. Hess B (1991) The role of Tamm-Horsfall glycoprotein and nephrocalcin in calcium oxalate monohydrate crystallization processes. Scanning Microsc 5: 689-696
44. Hess B (1992) Tamm-Horsfall glycoprotein-inhibitor or promoter of calcium oxalate monohydrate crystallization processes? Urol Res 20: 83-86
45. Hess B, Kok DJ (1996) Nucleation, growth and aggregation of stone-forming crystals. In: Coe FL, Favus MJ, Pak CYC, Parks JH. Preminger GM (eds) Kidney stones: medical and surgical management. Lippincott-Raven Philadelphia, pp 3-32
46. Hess B. Nakagawa Y. Coe FL (1989) Nephrocalcin isolated from human kidney stones is a defective calcium-oxalatemonohydrate crystal-aggregation inhibitor. In: Walker VR, Sutton RAL, Cameron EC. Pak CYC, Robertson WG (eds) Urolithiasis. Plenum. New York London, pp 137-139
47. Hesse A. Wuzel H, Vahlensieck W (1986) The excretion of glycosaminoglycans in the urine of calcium-oxalate-stone patients and healthy persons. Urol Int 41: 81-87
48. Hodgkinson A (1962) Citric acid excretion in normal adults and in patients with renal calculus. Clin Sci 23: 203-212
49. Howard JE. Thomas WC (1958) Some observations on rachitic rat cartilage of probable significance in the etiology of renal calculi. Trans Am Clin Climatol Assoc 70: 94-102
50. Hoyer JR (1995) Uropontin in urinary calcium stone formation. Miner Electrolyte Metab 20: 385-392
51. Hunt JS, McGiven AR, Grouvsky A, Lynn KL, Taylor MC (1994) Affinity-purified antibodies of defined specificity for use in a solid-phase microplate radioimmunoassay of human Tamm-Horsfall glycoprotein in urine. Biochem J 227: 957-963
52. Hwang TIS, Preminger GM, Poindexter J, Pak CYC (1988) Urinary glycosaminoglycans in normal subjects and patients with stones. J Urol 139: 995-997
53. Johansson G. Backman U, Danielson BG. Fellström B, Ljunghall S (1980) Biochemical and clinical effects of the prophylactic treatment of renal calcium stones with magnesium hydroxide. J Urol 124: 770-774
54. Kaiser ET, Bock SC (1989) Protein inhibitors of crystal growth. J Urol 141: 750-752
55. Kitamura T, Pak CYC (1982) Tamm and Horsfall glycoprotein does not promote spontaneous precipitation and crystal growth of calcium oxalate in vitro. J Urol 127: 1024-1026
56. Kohri K, Garside J, Blacklock NJ (1989) The effect of glycosaminoglycans on the crystallization of calcium oxalate. Br J Urol 63: 584-590
57. Kohri K, Suzuki Y, Yoshida K, Yamamoto K, Amasaki N, Yamate T, Umekawa T, Iguchi M, Sinohara H, Kurita T (1992) Molecular cloning and sequencing of cDNA encoding urinary stone protein, which is identical to osteopontin. Biochem Biophys Res Commun 184: 859-864
58. Kohri K, Nomura S, Kitamura Y, Nagata T, Yoshioka K, Iguchi M, Yamate T, Umekawa T. Suzuki Y, Sinohara H, Kurita T (1993) Structure and expression of the mRNA encoding urinary stone protein (osteopontin). J Biol Chem 268: 15180-15184
59. Kok DJ (1996) Inhibitors of calcium oxalate crystallization. In: Khan SR (ed) Calcium oxalate in biological systems. CRC, Boca Raton New York London Tokyo, pp 23-36
60. Kok DJ, Papapoulos SE, Bijvoet OLM (1986) Excessive crystal agglomeration with low citrate excretion in recurrent stone formers. Lancet I: 1056-1058
61. Lama G, Carbone MG, Marrone N, Russo P, Spagnolo G (1990) Promoters and inhibitors of calcium urolithiasis in children. Child Nephrol Urol 10: 81-84
62. Li MK, Blacklock NJ, Garside J (1985) Effects of magnesium on calcium oxalate crystallization. J Urol 133: 123-125
63. Martin X, Werness PG, Bergert JH, Smith LH (1984) Pentosan polysulfate as an inhibitor of calcium oxalate crystal growth. J Urol 132: 786-788
64. Menon M, Mahle CJ (1983) Urinary citrate excretion in patients with renal calculi. J Urol 129: 1158-1160
65. Meyer JL, Smith LH (1975) Growth of calcium oxalate crystals. II. Inhibition by natural crystal growth inhibitors. Invest Urol 13: 36-39
66. Michelacci YM, Glashan RQ, Schor N (1989) Urinary excretion of glycosaminoglycans in normal and stone forming subjects. Urol Int 44: 218-221
67. Michelacci YM, Boim MA, Bergamaschi CT, Rovigatti RM, Schor N (1992) Possible role for chondroitin sulfate in urolithiasis: in vivo studies in an experimental model. Clin Chim Acta 208: 1-8
68. Miyazawa K, Suzuki K, Tsugawa R (1989) The quantitative study of inhibitory effect of pentosan polysulfate and chlorophyllin on the experimental calcium oxalate stone. Jpn J Urol 80: 861-869
69. Nakagawa Y, Margolis HC, Yokoyama S, Kézdy FJ, Kaiser ET, Coe FL (1981) Purification and characterization of a calcium oxalate monohydrate crystal growth inhibitor from human kidney tissue culture medium. J Biol Chem 256: 3936-3944
70. Nakagawa Y, Abram V, Kézdy FJ, Kaiser ET, Coe FL (1983) Purification and characterization of the principal inhibitor of calcium oxalate monohydrate crystal growth in human urine. J Biol Chem 258: 12594-12600
71. Nakagawa Y. Abram V, Coe FL (1984) Isolation of calcium oxalate crystal growth inhibitor from rat kidney and urine. Am J Physiol 247: F765-F772
72. Nakagawa Y, Abram V, Parks JH. Lau HS-H, Kawooya JK, Coe FL (1985) Urine glycoprotein crystal growth inhibitors. Evidence for a molecular abnormality in calcium oxalate nephrolithiasis. J Clin Invest 76: 1455-1462
73. Nakagawa Y, Ahmed M, Hall SL, Deganello S, Coe FL (1987) Isolation from human calcium oxalate renal stones of nephrocalcin, a glycoprotein inhibitor of calcium oxalate crystal growth. Evidence that nephrocalcin from patients with calcium oxalate nephrolithiasis is deficient in gamma-carboxyglutamic acid. J Clin Invest 79: 1782-1787
74. Nakagawa Y. Netzer M, Coe FL (1990) Immunohistochemical localization of nephrocalcin (NC) to proximal tubule and thick ascending limb of Henle's loop (TALH) of human and mouse kidney (abstract) Kidney Int 37: 474
75. Nesse A. Garbossa G, Romero MC, Bogardo CE, Zanchetta JR (1992) Glycosaminoglycans in urolithiasis. Nephron 62: 36-39
76. Nicar MJ, Skula C, Sakhaee K, Pak CYC (1983) Low citrate excretion in nephrolithiasis. Urology 21: 8-14
77. Nikkilä MT (1989) Urinary glycosaminoglycan excretion in normal and stone-forming subjects: significant disturbance in recurrent stone formers. Urol Int 44: 157-159
78. Nishio S, Abe Y, Wakatsuki A, Iwata H, Ochi K, Takeuchi M, Matsumoto A (1985) Matrix glycosaminoglycan in urinary stones. J Urol 134: 503-505
79. Norman RW, Scurr DS. Robertson WG, Peacock M (1984) Inhibition of calcium oxalate crystallisation by pentosan polysulphate in control subjects and stone formers. Br J Urol 56: 594-598
80. O'Brien MM, Uhlemann I, Mclntosh HW (1967) Urinary pyrophosphate in normal subjects and in stone formers. Can Med Assoc J 96: 100-103
81. Oreopoulos DG, Walker D, Akriotis DJ, Roncari DAK, Husdan H, Symvoulidis A, Deveber GA, Rapoport A, Reid DBW (1975) Excretion of inhibitors of calcification in urine. I. Findings in control subjects and patients with renal stones. Can Med Assoc J 112: 827-832
82. Osswald H, Weinheimer G. Schutt I-D, Ernst W (1989) Effective prevention of calcium-oxalate crystal formation in vitro and in vivo by pentosan polysulfate. In: Walker VR. Sutton RAL, Cameron ECB, Pak CYC, Robertson WG (eds) Urolithiasis. Plenum, New York London, pp 141-144
83. Pak CYC (1987) Citrate and renal calculi. Miner Electrolyte Metab 13: 257-266
84. Pak CYC (1994) Citrate and renal calculi: an update. Miner Electrolyte Metab 20: 371-377
85. Pak CYC, Holt K, Zerwekh J. Barilla DE (1978) Effects of orthophosphate therapy on the crystallization of calcium salts in urine. Miner Electrolyte Metab 2: 147-154
86. Pak CYC, Holt K, Zerwekh JE (1979) Attenuation by monosodium urate of the inhibitory effect of glycosaminoglycans on calcium oxalate nucleation. Invest Urol 17: 138-140
87. Pylypchuk G, Ehrig V. Wilson DR ((1979) Differences in urine crystalloids, urine saturation with brushite and urine inhibitors of calcification between persons with and persons without recurrent kidney stone formation. Can Med Assoc J 120: 658-665
88. Roberts SD, Resnick MI (1986) Glycosaminoglycans content of stone matrix. J Urol 135: 1078-1083
89. Robertson WG, Peacock M (1972) Calcium oxalate crystalluria and inhibitors of crystallisation in recurrent renal stoneformers. Clin Sci 43: 499-506
90. Robertson WG, Scurr DS (1986) Modifiers of calcium crystallization found in urine. I. Studies with a continuous crystallizer using an artifical urine. J Urol 135: 1322-1326
91. Robertson WG. Peacock M, Nordin BEC (1968) Activity products in stone-forming and non-stone-forming urines. Clin Sci 34: 579-594
92. Robertson WG, peacock M, Nordin BEC (1973) Inhibitors of the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 43: 31-37
93. Robertson WG, Peacock M, Heyburn PJ, Marshall DH. Clark PB (1978) Risk factors in calcium stone disease of the urinary tract. Br J Urol 50: 449-454
94. Robertson WG, Scurr DS, Bridge CM (1981) Factors influencing the crystallization of calcium oxalate in urine - a critique. J Cryst Growth 53: 182-194
95. Rose GA, Sulaiman S (1982) Tamm-Horsfall mucoprotein promotes calcium phosphate crystal formation in urine: quantitative studies. J Urol 127: 177-179
96. Rudman D, Kutner MH, Redd SC, Waters WG, Gerron GG, Bleier J (1982) Hypocitraturia in calcium nephrolithiasis. J Endocrinol Metab 55: 1052-1057
97. Rushton HG, Spector M (1982) Effects of magnesium deficieny on intratubular calcium oxalate formation and crystalluria in hyperoxaluric rats. J Urol 127: 598-604
98. Russell RGG. Hodgkinson A (1966) The urinary excretion of inorganic pyrophosphate by normal subjects and patients with renal calculus. Clin Sci 31: 51-62
99. Ryall RL (1996) Glycosaminoglycans, proteins and stone formation: adult themes and child's play. Pediatr Nephrol 10: 656-666
100. Ryall RL, Marshall VR (1983) The value of the 24hr urine analysis in the assessment of stone formers attending a general hospital outpatient clinic. Br J Urol 55: 1-5
101. Ryall RL. Marshall VR ( 1984) The relationship between urinary inhibitory activity and endogenous concentrations of glycosaminoglycans and uric acid: comparison of urines from stone formers and normal subjects. Clin Chim Acta 141: 197-204
102. Ryall RL. Marshall VR (1990) Investigation and management of idiopathic urolithiasis. In: Wickham JEA. Buck AC (eds) Renal tract stone: metabolic basis and clinical practice. Churchill Livingstone. Edinburgh London Melbourne New York, pp 307-331
103. Ryall RL, Stapleton AM F (1995) Urinary macromolecules in calcium oxalate stone and crystal matrix: good, bad, or indifferent? In: Khan SR (ed) Calcium oxalate in biological systems. CRC. Boca Raton New York London Tokyo, pp 265-290
104. Ryall RL, Harnett RM, Marshall VR (1981) The effect of urine, pyrophosphate, citrate, magnesium and glycosaminoglycans on the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 112: 349-356
105. Ryall RL, Darroch JN, Marshall VR (1984) The evaluation of risk factors in male stone formers attending a general hospital out-patient clinic. Br J Urol 56: 116-121
106. Ryall RL, Hibberd CM, Marshall VR (1985) A method for studying inhibitory activity in whole urine. Urol Res 13: 285-289
107. Ryall RL. Hibberd CM, Mazzachi BC, Marshall VR (1986) Inhibitory activity of whole urine: a comparison of urines from stone formers and normal subjects. Clin Chim Acta 154: 59-68
108. Ryall RL. Harnett RM, Hibberd CM, Mazzachi BC, Mazzachi RD. Marshall VR (1987) Urinary risk factors in calcium oxalate stone disease: a comparison of men and women. Br J Urol 60: 480-488
109. Ryall RL, Grover PK, Harnett RM. Hibberd CM. Marshall VR (1989) Small molecular weight inhibitors. In: Walker VR. Sutton RAL, Cameron ECB. Pak CYC, Robertson WG (eds) Urolithiasis. Plenum, New York London, pp 91- 96
110. Ryall RL, Harnett RM, Hibberd CM. Edyvanc K.A, Marshall VR (1991) Effects of chondroitin sulphate, human serum albumin and Tamm-Horsfall mucoprotein on calcium oxalate crystallization in undiluted human urine. Urol Res 19: 181-188
111. Ryall RL, Grover PK, Stapleton AMF. Barrel! DK, Tang Y. Moritz RL, Simpson RJ (1995) The urinary Fl activation peptide of human prothrombin is a potent inhibitor of calcium oxalate crystallization in undiluted human urine in vitro. Clin Sci 89: 533-541
112. Sabbatini L (1901) Archi Ital Biol 36: 397 (cited in [42])
113. Salier J-P (1990) Inter-a-trypsin inhibitor: emergence of a family within the Kunitz-type protease inhibitor superfamily. TIBS 15: 435-439
114. Samuell CT (1981) A study of glycosaminoglycan excretion in normal and stone-forming subjects using a modified cetylpyridinium chloride technique. Clin Chim Acta 117: 63-73
115. Sarig S, Gard N, Azoury R, Wax Y, Perlberg S (1982) A method for discrimination between calcium oxalate kidney stone formers and normals. J Urol 128: 645-649
116. Schwüle PO, Scholz D, Paulus M, Engelhard! W, Segel A (1979) Citrate in daily and fasting urine. Results of controls, patients with recurrent idiopathic calcium urolithiasis and primary hyperparathyroidism. Invest Urol 16: 457-462
117. Schwüle PO, Scholz D, Schwüle K, Leutschaft R, Goldberg I, Segel A (1982) Citrate in urine and serum and associated variables in subgroups of urolithiasis. Nephron 31: 194-202
118. Scurr DS, Robertson WG (1986) Modifiers of calcium oxalate crystallization found in urine. II. Studies on their mode of action in an artificial urine. J Urol 136: 128-131
119. Shiraga H, Min W, VanDusen WJ, dayman MD, Miner D, Terrell CH, Sherbotie JR, Foreman JW, Przysiecki C, Neilson EG, Hoyer JR (1992) Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proc Natl Acad Sci USA 89: 426-430
120. Shorr E, Almay TP, Sloan MH, Taussky H, Toscani V (1942) The relation between the urinary excretion of citric acid and calcium: its implications for urinary calcium stone formation. Science 96: 587-588
121. Shum DKY, Gohel MDI (1993) Separate effects of urinary chondroitin sulphate and heparan sulphate upon the crystallization of urinary calcium oxalate: differences between stone formers and normal controls. Clin Sci 85: 33-39
122. S0renson S, Hansen K, Bak S, Justesen SJ (1990) An unidentified macromolecular inhibitory constituent of calcium oxalate crystal growth in human urine. Urol Res 18: 373-379
123. Springmann KE, Drach GW, Gottung B, Randolph AD (1986) Effects of human urine on aggregation of calcium oxalate crystals. J Urol 135: 69-71
124. Stapleton AMF, Ryall FL (1995) Blood coagulation proteins and urolithiasis are linked: crystal matrix protein is the Fl activation peptide of human prothrombin. Br J Urol 75: 712-719
125. Stapleton AMF. Seymour AE. Brennan JS, Doyle IR. Marshall VR. Ryall RL (1993) The immunohislochemical distribution and quantification of crystal matrix protein. Kidney hit 44: 817-824
126. Stapleton AMF. Simpson RJ. Ryall RL (1995) Crystal matrix protein is related to human prothrombin. Biochem Biophys Res Commun 195: 1199-1203
127. Stapleton AMF, Dawson CJ. Grover PK. Hohman A. Comacchio R. Boswarva V, Tang Y, Ryall RL (1996) Further evidence linking urolithiasis and blood coagulation: urinary prothrombin fraement 1 is present in stone matrix. Kidney Int 49: 880-888
128. Stapleton AMF. Timme TL, Ryall RL (1996) The gene expression of human prothrombin in the human kidney: its potential relevance to kidney stone disease. In: Pak CYC, Resnick MI. Preminger GM (eds) Urolithiasis 1996. Millet. Dallas, pp 543-545
129. Sutor DJ (1969) Growth studies of calcium oxalate in the presence of various ions and compounds. Br.I Urol41: 171-178
130. Suzuki K, Ryall RL (1996) The effect of heparan sulphate on the crystallization of calcium oxalate in undiluted, ultrafiltered human urine. Br J Urol 78: 15-21
131. Suzuki K. Miyazawa K. Tsugawa R (1989) Inhibitory effect of sodium pentosan polysulfate on the formation, growth and aggregation of calcium oxalate in vitro. Jpn J Urol 80: 526-531
132. Tang Y, Grover PK, Moritz RL, Simpson RJ, Ryall RL (1995) Is nephrocalcin related to the urinary derivative (bikunin) of inter-a-trypsin inhibitor? Br J Urol 75: 425-430
133. Thomas WC, Howard JE (1959) Studies on the mineralizing propensity of urine from patients with and without renal calculi. Trans Assoc Am Physicians 72: 181-187
134. Welshman SG, McGeown MG (1972) A quantitative investigation of the effects on the growth of calcium oxalate crystals of potential inhibitors. Br J Urol 44: 677-680
135. Welshman SG, McGeown MG (1975) the relationship of the urinary cations calcium, magnesium, sodium and potassium in patients with renal calculi. Br J Urol 47: 237-242
136. Welshman SG, McGeown MG (1976) Urinary citrate excretion in stone-formers and normal controls. Br J Urol 48: 7-11
137. Wessier E (1971) The nature of the non-ultrafiltrable glycosaminoglycans of normal human urine. Biochem J 122: 373-384
138. Wikström B. Danielson BG, Ljunghall S, McGuire M, Russell RGG (1983) Urinary pyrophosphate excretion in renal stone formers with normal and impaired renal function. World J Urol 1: 150-154
139. Worcester EM, Blumenthal SS, Beshensky A (1992) The calcium oxalate crystal growth inhibitor protein produced by mouse kidney cortical cells in culture is osteopontin. J Bone Miner Res 7: 1029-1036
140. Worcester EM, Sebastian JL, Hiatt JG, Beshensky AM, Sadowski JA (1993) The effect of warfarin on urine calcium oxalate crystal growth inhibition and urinary excretion of calcium and nephrocalcin. Calcif Tissue Int 53: 242-248
141. Yamaguchi S, Yoshioka T. Utsonomiya M, Koide T, Osafune M, Okuyama A, Sonoda T (1993) Heparan sulfate in the stone matrix and its inhibitory effect on calcium oxalate crystallization. Urol Res 21: 187-192